# Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

> **NCT03485209** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 350 (actual)

## Conditions studied

- Colorectal Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Exocrine Pancreatic Cancer
- Carcinoma, Squamous Cell of Head and Neck

## Interventions

- **DRUG:** tisotumab vedotin
- **DRUG:** pembrolizumab
- **DRUG:** carboplatin
- **DRUG:** cisplatin

## Key facts

- **NCT ID:** NCT03485209
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-25
- **Primary completion:** 2026-03-20
- **Final completion:** 2027-03-31
- **Target enrollment:** 350 (ACTUAL)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03485209

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03485209, "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03485209. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*